This HTML5 document contains 87 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n19https://global.dbpedia.org/id/
umbel-rchttp://umbel.org/umbel/rc/
yagohttp://dbpedia.org/class/yago/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n22http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
freebasehttp://rdf.freebase.com/ns/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
dbpedia-arhttp://ar.dbpedia.org/resource/
owlhttp://www.w3.org/2002/07/owl#
dbpedia-ithttp://it.dbpedia.org/resource/
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
goldhttp://purl.org/linguistics/gold/
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Lexatumumab
rdf:type
yago:Chemical114806838 yago:Relation100031921 umbel-rc:DrugProduct yago:Abstraction100002137 owl:Thing dbo:Drug yago:Thing100002452 yago:Substance100019613 yago:WikicatMonoclonalAntibodies yago:WikicatMonoclonalAntibodiesForTumors yago:Part113809207 yago:MonoclonalAntibody115029781 yago:Compound114818238 yago:Unit109465459 yago:Protein114728724 yago:Material114580897 yago:Molecule114682133 wikidata:Q8386 n22:ChemicalObject dbo:ChemicalSubstance dbo:MonoclonalAntibody yago:Macromolecule114944888 yago:OrganicCompound114727670 yago:Matter100020827 yago:Antibody115027189 yago:PhysicalEntity100001930
rdfs:label
Lexatumumab Lexatumumab لكساتوموماب
rdfs:comment
Il lexatumumab o ETR2-ST01, è un anticorpo monoclonale di tipo umano, che viene studiato per il trattamento di forme di tumore. Esso è stato sviluppato dalla , Inc.. Il farmaco agisce sull'antigene: -R2. لكساتوموماب جسم مضاد وحيد النسيلة بشري تجري عليه التجارب السريرية لاستخدامه في علاج السرطان. Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment of cancer. HGS-ETR2 antibodies were generated by Human Genome Sciences through a collaboration with Cambridge Antibody Technology. Development was discontinued in 2015.
dcterms:subject
dbc:Experimental_cancer_drugs dbc:Monoclonal_antibodies_for_tumors
dbo:wikiPageID
9700526
dbo:wikiPageRevisionID
1058530797
dbo:wikiPageWikiLink
dbr:Cancer dbr:Human dbr:Cambridge_Antibody_Technology dbr:Human_Genome_Sciences dbc:Monoclonal_antibodies_for_tumors dbr:Monoclonal_antibody dbr:TRAIL-R2 dbc:Experimental_cancer_drugs
owl:sameAs
dbpedia-it:Lexatumumab freebase:m.02ppkg1 dbpedia-ar:لكساتوموماب n19:BWdQ yago-res:Lexatumumab wikidata:Q1112374
dbp:wikiPageUsesTemplate
dbt:Fdacite dbt:Drugbox dbt:Monoclonals_for_tumors dbt:Monoclonal-antibody-stub dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Antineoplastic-drug-stub dbt:Keggcite dbt:Drugbankcite
dbp:atcPrefix
none
dbp:c
6346
dbp:casNumber
845816
dbp:chemspiderid
none
dbp:h
9832
dbp:kegg
D06611
dbp:n
1720
dbp:o
2002
dbp:s
42
dbp:source
u
dbp:target
TRAIL-R2
dbp:type
mab
dbp:unii
967
dbp:verifiedfields
changed
dbp:verifiedrevid
458270193
dbp:watchedfields
changed
dbo:abstract
Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment of cancer. HGS-ETR2 antibodies were generated by Human Genome Sciences through a collaboration with Cambridge Antibody Technology. Development was discontinued in 2015. Il lexatumumab o ETR2-ST01, è un anticorpo monoclonale di tipo umano, che viene studiato per il trattamento di forme di tumore. Esso è stato sviluppato dalla , Inc.. Il farmaco agisce sull'antigene: -R2. لكساتوموماب جسم مضاد وحيد النسيلة بشري تجري عليه التجارب السريرية لاستخدامه في علاج السرطان.
dbp:mabType
mab
gold:hypernym
dbr:Antibody
prov:wasDerivedFrom
wikipedia-en:Lexatumumab?oldid=1058530797&ns=0
dbo:wikiPageLength
2767
dbo:casNumber
845816-02-6
dbo:fdaUniiCode
967Q0SJD77
dbo:kegg
D06611
foaf:isPrimaryTopicOf
wikipedia-en:Lexatumumab